Harbor Capital Advisors Inc. Sells 22,228 Shares of Haemonetics Corporation $HAE

Harbor Capital Advisors Inc. lowered its position in shares of Haemonetics Corporation (NYSE:HAE) by 51.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 20,631 shares of the medical instruments supplier’s stock after selling 22,228 shares during the quarter. Harbor Capital Advisors Inc.’s holdings in Haemonetics were worth $1,654,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Federated Hermes Inc. grew its holdings in shares of Haemonetics by 1,405.7% in the 3rd quarter. Federated Hermes Inc. now owns 46,104 shares of the medical instruments supplier’s stock valued at $2,247,000 after buying an additional 43,042 shares during the period. Isthmus Partners LLC raised its stake in Haemonetics by 36.5% during the 3rd quarter. Isthmus Partners LLC now owns 61,702 shares of the medical instruments supplier’s stock worth $3,007,000 after buying an additional 16,505 shares during the period. Fort Washington Investment Advisors Inc. OH raised its stake in Haemonetics by 36.2% during the 3rd quarter. Fort Washington Investment Advisors Inc. OH now owns 706,312 shares of the medical instruments supplier’s stock worth $34,426,000 after buying an additional 187,630 shares during the period. Norges Bank bought a new position in Haemonetics during the second quarter worth about $36,822,000. Finally, Skylands Capital LLC grew its stake in Haemonetics by 195.4% in the third quarter. Skylands Capital LLC now owns 81,369 shares of the medical instruments supplier’s stock valued at $3,966,000 after acquiring an additional 53,819 shares during the period. Institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Performance

HAE opened at $56.79 on Friday. The company has a market capitalization of $2.64 billion, a price-to-earnings ratio of 15.64, a P/E/G ratio of 1.11 and a beta of 0.36. The business’s 50-day moving average price is $60.87 and its two-hundred day moving average price is $65.10. Haemonetics Corporation has a 1 year low of $47.31 and a 1 year high of $87.32. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.75 and a quick ratio of 1.15.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.27 by $0.04. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.The company had revenue of $338.97 million during the quarter, compared to analysts’ expectations of $331.90 million. During the same period in the prior year, the firm earned $1.19 earnings per share. Haemonetics’s revenue for the quarter was down 2.7% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. Equities analysts expect that Haemonetics Corporation will post 4.55 EPS for the current fiscal year.

Analysts Set New Price Targets

HAE has been the subject of several recent analyst reports. CJS Securities upgraded Haemonetics to a “strong-buy” rating in a report on Thursday, December 11th. JPMorgan Chase & Co. lifted their price objective on Haemonetics from $62.00 to $74.00 and gave the company a “neutral” rating in a report on Friday, December 12th. Barrington Research set a $94.00 price objective on Haemonetics in a research report on Friday, February 6th. Robert W. Baird set a $81.00 target price on Haemonetics in a research note on Friday, February 6th. Finally, Citigroup dropped their target price on shares of Haemonetics from $75.00 to $70.00 and set a “neutral” rating on the stock in a report on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $83.89.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.